AIDS-related and non-AIDS-related mortality in the Asia-Pacific region in the era of combination antiretroviral treatment

AIDS

Volumn 23, Issue 17, 2009, Pages 2323-2336

  Falster, Kathleen ^a,b   Choi, Jun Yong ^c   Donovan, Basil ^a,d   Duncombe, Chris ^a,e   Mulhall, Brian ^f   Sowden, David ^g   Zhou, Jialun ^a   Law, Matthew G ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c Yonsei University College of Medicine   (South Korea)

^d SYDNEY EYE HOSPITAL   (Australia)

^e THAI RED CROSS AIDS RESEARCH CENTRE   (Thailand)

^f UNIVERSITY OF SYDNEY   (Australia)

^g Geriatrics and Rehabilitation   (Australia)

Author keywords

AIDS; Antiretroviral therapy; Causes of death; Cohort studies; Competing risks models; Highly active; HIV; Survival analysis

Indexed keywords

VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ACUTE LYMPHOCYTIC LEUKEMIA; ADULT; ANUS CANCER; ARTICLE; ASIA; ATHEROMA; AUSTRALIA; BACTERIAL INFECTION; BRAIN TUMOR; CARDIOPULMONARY ARREST; CAUSE OF DEATH; CD4+ T LYMPHOCYTE; COLON CANCER; CONTROLLED STUDY; DIABETES MELLITUS; DRUG TOXICITY; ENCEPHALITIS; EPILEPSY; ESOPHAGUS CANCER; FEMALE; FOLLOW UP; GASTROINTESTINAL TUMOR; HEAD INJURY; HEART ARREST; HEART FAILURE; HEART INFARCTION; HEPATITIS B; HEPATITIS C; HEPATORENAL SYNDROME; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; INCIDENCE; INFECTION RISK; ISCHEMIC HEART DISEASE; KENNEDY DISEASE; KIDNEY FAILURE; LIVER CANCER; LIVER CIRRHOSIS; LIVER FAILURE; LOWEST INCOME GROUP; LUNG CANCER; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MELANOMA; MESOTHELIOMA; MORTALITY; PANCREATITIS; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; STROKE; SUICIDE; TRAFFIC ACCIDENT; VASCULAR DISEASE; VIRUS LOAD;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ASIA; AUSTRALIA; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; CD4 LYMPHOCYTE COUNT; FEMALE; HIV-1; HUMANS; LIVER DISEASES; MALE; MIDDLE AGED; NEOPLASMS; RISK FACTORS; SOCIOECONOMIC FACTORS;

EID: 70449370277     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328331910c     Document Type: Article

References (39)

1. Egger M, Hirschel B, Francioli P, Sudre P, Wirz M, Flepp M, et al. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. BMJ 1997; 315:1194-1199.
2. Ewings FM, Bhaskaran K, McLean K, Hawkins D, Fisher M, Fidler S, et al. Survival following HIV infection of a cohort followed up from seroconversion in the UK. AIDS 2008; 22: 89-95.
3. Mocroft A, Ledergerber B, Katlama C, Kirk O, Reiss P, Monforte AdA, et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 2003; 362:22-29.
4. Mocroft A, Vella S, Benfield TL, Chiesi A, Miller V, Gargalianos P, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. Lancet 1998; 352:1725-1730.
5. Nash D, Katyal M, Shah S. Trends in predictors of death due to HIV-related causes among persons living with AIDS in New York City: 1993-2001. J Urban Health 2005; 82:584-600.
6. Ormaasen V, Sandvik L, Dudman SG, Bruun JN. HIV related and non-HIV related mortality before and after the introduction of highly active antiretroviral therapy (HAART) in Norway compared to the general population. Scand J Infect Dis 2007; 39:51-57.
7. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853-860.
8. Babiker A, Darbyshire J, Pezzotti P, Porter K, Rezza G, Walker SA, et al. Changes over calendar time in the risk of specific first AIDS-defining events following HIV seroconversion, adjusting for competing risks. Int J Epidemiol 2002; 31:951-958.
9. Smit C, Geskus R, Walker S, Sabin C, Coutinho R, Porter K, Prins M. Effective therapy has altered the spectrum of cause-specific mortality following HIV seroconversion. AIDS 2006; 20:741-749
10. Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 2008; 372:293-299.
11. Bhaskaran K, Hamouda O, Sannes M, Boufassa F, Johnson AM, Lambert PC, Porter K. Changes in the risk of death after HIV seroconversion compared with mortality in the general population. JAMA 2008; 300:51-59.
12. Lohse N, Hansen AB, Pedersen G, Kronborg G, Gerstoft J, Sorensen HT, et al. Survival of persons with and without HIV infection in Denmark, 1995-2005. Ann Intern Med 2007; 146:87-95.
13. Petoumenos K, Law MG. Risk factors and causes of death in the Australian HIV Observational Database. Sex Health 2006; 3:103-112.
14. Mocroft A, Brettle R, Kirk O, Blaxhult A, Parkin JM, Antunes F, et al. Changes in the cause of death among HIV positive subjects across Europe: results from the EuroSIDA study. AIDS 2002; 16:1663-1671.
15. Pacheco AG, Tuboi SH, Faulhaber JC, Harrison LH, Schechter M. Increase in non-AIDS related conditions as causes of death among HIV-infected individuals in the HAART era in Brazil. PLoS ONE 2008; 3:e1531.
16. Palella FJ Jr, Baker RK, Moorman AC, Chmiel JS, Wood KC, Brooks JT, Holmberg SD. Mortality in the highly active anti-retroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr 2006; 43:27-34.
17. Sackoff JE, Hanna DB, Pfeiffer MR, Torian LV. Causes of death among persons with AIDS in the era of highly active antire-troviral therapy: New York City. Ann Intern Med 2006; 145:397-406
18. d'Arminio A, Sabin CA, Phillips AN, Reiss P, Weber R, Kirk O, et al. Cardio-and cerebrovascular events in HIV-infected persons. AIDS 2004; 18:1811-1817.
19. Fontas E, van Leth F, Sabin CA, Friis-Moller N, Rickenbach M, d'Arminio Monforte A, et al. Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles? J Infect Dis 2004; 189:1056-1074.
20. Friis-Moller N, Reiss P, Sabin CA, Weber R, Monforte A, El-Sadr W, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007; 356:1723-1735.
21. Friis-Moller N, Sabin CA, Weber R, d'Arminio Monforte A, El-Sadr WM, Reiss P, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003; 349: 1993-2003.
22. Braitstein P, Brinkhof MW, Dabis F, Schechter M, Boulle A, Miotti P, et al. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 2006; 367:817-824
23. Australian HIV Observational Database. Rates of combination antiretroviral treatment change in Australia, 1997-2000. HIV Med 2002 3 28-36.
24. Zhou J, Kumarasamy N, Ditangco R, Kamarulzaman A, Lee CK, Li PC, et al. The TREAT Asia HIV Observational Database: baseline and retrospective data. J Acquir Immune Defic Syndr 2005; 38:174-179
25. Centers for Disease Control. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992; 41:1-19.
26. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999; 18:695-706.
27. Fine JP, Gray RJ. A proportional hazards model for the sub-distribution of a competing risk. J Am Stat Assoc 1999; 446:496-509.
28. Lunn M, McNeil D. Applying Cox regression to competing risks. Biometrics 1995; 51:524-532.
29. World Bank. World Bank list of economies: July 2008. New York: World Bank; 2008.
30. Baker JV, Peng G, Rapkin J, Abrams DI, Silverberg MJ, MacArthur RD, et al. CD4R count and risk of non-AIDS diseases following initial treatment for HIV infection. AIDS 2008; 22:841-848.
31. Emery S, Neuhaus JA, Phillips AN, Babiker A, Cohen CJ, Gatell JM,etal. Majorclinicaloutcomesinantiretroviral therapy(ART)-naive participants and in those not receiving ART at baseline in the SMART study. J Infect Dis 2008; 197:1133-1144.
32. Lau B, Gange SJ, Moore RD. Risk of non-AIDS-related mortality may exceed risk of AIDS-related mortality among individuals enrolling into care with CD4R counts greater than 200 cells/ mm3. J Acquir Immune Defic Syndr 2007; 44:179-187.
33. Smith DK, Gardner LI, Phelps R, Hamburger ME, Carpenter C, Klein RS, et al. Mortality rates and causes of death in a cohort of HIV-infected and uninfected women, 1993-1999. J Urban Health 2003; 80:676-688.
34. Weber R, Sabin CA, Friis-Moller N, Reiss P, El-Sadr WM, Kirk O, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 2006; 166:1632-1641.
35. Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 2007; 370:59-67.
36. Monforte A, Abrams D, Pradier C, Weber R, Reiss P, Bonnet F, et al. HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies. AIDS 2008; 22:2143-2153.
37. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004; 11:97-107.
38. Lavanchy D. The global burden of hepatitis C. Liver Int 2009; 29 (Suppl 1):74-81.
39. WHO, UNICEF, UNAIDS. Towards universal access: scaling up priority HIV/AIDS interventions in the health sector: Progress report 2008. Geneva: WHO; 2008